I should think

--------------------------------------------------
Note added at 7 mins (2007-10-17 21:10:03 GMT)
--------------------------------------------------

Effects of cyproterone acetate and a long-acting LHRH analogue on ...Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. R B Paisey, C Kadow, ...
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1290276


--------------------------------------------------
Note added at 20 mins (2007-10-17 21:23:25 GMT)
--------------------------------------------------

http://www.ephmra.org/PDF/Poster NFC 30 May 06 FINAL.pdf

Rule 2. Long-acting and Ordinary Forms
Long-acting as used in the New Form Code classification refers to the form of a preparation and not to the active
ingredient. Long-acting (Retard) forms are only classified as long-acting if this information is provided by the manufacturer
in the literature, if implied in the name e.g. Depo Provera (Upjohn) or in the pack description. If the ingredients
are known pharmacologically to have a long duration of action and the manufacturer does not specify that the
form is long-acting, the form is classified as ordinary. The manufacturer’s marketing policy must not be changed by
the classification. Any form, which cannot be classified as ordinary e.g. long-acting, retard, depot etc is to be classified
as long-acting.
Injectable preparations with a special ‘long-acting’ formulation e.g. oil, oily suspension, aqueous suspension, ester etc for
intramuscular, subcutaneous, intra-articular and intrasynovial administration are also classified as long-acting.
Note that forms described as delayed action or delayed release are classified as ordinary unless they are also long-acting.

--------------------------------------------------
Note added at 23 mins (2007-10-17 21:25:55 GMT)
--------------------------------------------------

delayed action or delayed release is not necessarily the same as long-acting